ticovac® junior inj.su.pfs (1,00-1,38)mcg.0,25ml (τιμή στόχος 1,2 mg)
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - encephalitis, tick borne, inactivated, whole virus - inj.su.pfs (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - (1,00-1,38)mcg.0,25ml (τιμή στόχος 1,2 mg) - encephalitis, tick borne, inactivated, whole virus 1,38mcg - encephalitis, tick borne, inactivated, whole virus
ticovac junior 0.25ml/dose suspension for injection in pre-filled syringe
pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - tick-borne encephalitis virus - suspension for injection in pre-filled syringe - 0.25ml/dose - tick-borne encephalitis virus (8000004795) 1,19ug
coxevac
ceva santé animale - αδρανοποιημένο εμβόλιο coxiella burnetii, στέλεχος nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.
coxevac ενεσιμο εναιωρημα
ceva sante animale, libourne, france (0000006753) zi la ballastiere,,,33500 libourne,fr - inactivated coxiella burnetii, strain nine mile - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - inactivated coxiella burnetii, strain nine mile 72,00 inj.susp 0 - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - Αίγες; Βοοειδή - Χρόνοι αναμονής: Βοοειδή 0 Ημέρες Κρέας και εδώδιμοι ιστοί, γάλα; Αίγες 0 Ημέρες Κρέας και εδώδιμοι ιστοί, γάλα
poliovaccine ssi ενεσιμο διαλυμα σε προγεμισμενη συριγγα
statens serum institut, denmark (0000005700) artillerivej 5,, dk-2300 copenhagen s - poliovirus vaccine; poliovirus vaccine; poliovirus vaccine - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ - 8000034777 poliovirus vaccine 40.000000 du; 8000034777 poliovirus vaccine 8.000000 du; 8000034777 poliovirus vaccine 32.000000 du - poliomyelitis, trivalent, inactivated, whole virus
poliovaccine/ajv inj.so.pfs
aj vaccines a/s, denmark artillerivej 5, dk-2300 copenhagen s +45 7229 7000 - poliovirus vaccine; poliovirus vaccine; poliovirus vaccine - inj.so.pfs (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - poliovirus vaccine 40du; poliovirus vaccine 8du; poliovirus vaccine 32du - poliomyelitis, trivalent, inactivated, whole virus
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - (αιμοσυγκολλητίνη και νευραμινιδάση) του στελέχους Α / Βιετνάμ / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - Εμβόλια - Ενεργός ανοσοποίηση έναντι του υποτύπου h5n1 του ιού της γρίπης Α. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
gyno-canesten 500mg vaginal capsule, soft
bayer hellas abee (0000012381) 6-8 agisilaou street, marousi, attiki, 15123 - clotrimazole - vaginal capsule, soft - 500mg - clotrimazole (0023593751) 500mg
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - Εμβόλια - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - Εμβόλια - active immunisation against h5 subtype of influenza a virus.